Analysts' ratings for Gilead Sciences GILD over the last quarter vary from bullish to bearish, as provided by 15 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 10 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 3 | 0 | 0 | 0 |
| 2M Ago | 1 | 5 | 3 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $116.27, with a high estimate of $140.00 and a low estimate of $84.00. Observing a 12.37% increase, the current average has risen from the previous average price target of $103.47.
Decoding Analyst Ratings: A Detailed Look
The analysis of recent analyst actions sheds light on the perception of Gilead Sciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Chris Schott | JP Morgan | Raises | Overweight | $130.00 | $120.00 |
| Matthew Harrison | Morgan Stanley | Raises | Overweight | $130.00 | $123.00 |
| Tim Anderson | B of A Securities | Raises | Buy | $126.00 | $116.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $140.00 | $120.00 |
| Hartaj Singh | Oppenheimer | Raises | Outperform | $132.00 | $115.00 |
| James Shin | Deutsche Bank | Raises | Buy | $120.00 | $80.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $90.00 | $84.00 |
| Salveen Richter | Goldman Sachs | Raises | Neutral | $96.00 | $85.00 |
| Evan Seigerman | BMO Capital | Raises | Outperform | $115.00 | $110.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $120.00 | $105.00 |
| Joseph Catanzaro | Piper Sandler | Raises | Overweight | $110.00 | $105.00 |
| Matthew Harrison | Morgan Stanley | Raises | Overweight | $123.00 | $113.00 |
| Brian Abrahams | RBC Capital | Maintains | Sector Perform | $84.00 | $84.00 |
| Chris Schott | JP Morgan | Raises | Overweight | $115.00 | $105.00 |
| Matthew Harrison | Morgan Stanley | Raises | Overweight | $113.00 | $87.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Gilead Sciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Gilead Sciences's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
For valuable insights into Gilead Sciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Gilead Sciences analyst ratings.
Discovering Gilead Sciences: A Closer Look
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Gilead Sciences: Financial Performance Dissected
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Gilead Sciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.4% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Gilead Sciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 23.56%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Gilead Sciences's ROE excels beyond industry benchmarks, reaching 9.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Gilead Sciences's ROA excels beyond industry benchmarks, reaching 3.14%. This signifies efficient management of assets and strong financial health.
Debt Management: Gilead Sciences's debt-to-equity ratio is below the industry average at 1.38, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: Simplified
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
